Jim Shannon – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Jim Shannon on 2016-01-12.

To ask the Secretary of State for Health, what assessment he has made of the effect of the negative interim NICE Appraisal Committee Decision on nivolumab for squamous non-small cell lung cancer on patients.

George Freeman

No such assessment has been made. The National Institute for Health and Care Excellence (NICE) is currently appraising nivolumab (Opdivo) for squamous non-small cell lung cancer and has not yet issued its final guidance.

In developing its technology appraisal guidance, NICE works closely with stakeholders, including manufacturers. NICE’s consultation on its draft guidance closed on 19 January 2016.

In the absence of NICE guidance, it is for commissioners to make funding decisions based on the available evidence.